2010
Extrapyramidal side effects
Caroff S, Miller D, Rosenheck R. Extrapyramidal side effects. 2010, 156-172. DOI: 10.1017/cbo9780511712265.010.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersExtrapyramidal side effectsDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsSide effectsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisCliniciansConclusion and implications for practice and policy
Rosenheck R, Stroup T, Lieberman J. Conclusion and implications for practice and policy. 2010, 288-306. DOI: 10.1017/cbo9780511712265.018.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisCliniciansFamily outcomes
Perlick D, Kaczynski R, Rosenheck R. Family outcomes. 2010, 133-155. DOI: 10.1017/cbo9780511712265.009.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsFamily outcomesDrugsPharmaceutical companiesSpecific outcomesOutcomesStatistical analysisClinicians
2009
Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck RA, Sernyak MJ. Developing A Policy For Second-Generation Antipsychotic Drugs. Health Affairs 2009, 28: w782-w793. PMID: 19622538, DOI: 10.1377/hlthaff.28.5.w782.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsAntipsychotic drugsRisk/benefit profileSecond-generation antipsychotic drugsMetabolic side effectsTreatment of schizophreniaAdverse eventsBenefit profileLower riskOld drugsSide effectsPrior authorizationDrugsCheaper drugsGeneric drugsEducational preparationWidespread implementationGood acceptanceSuch proceduresAntipsychoticsPatientsTherapySchizophrenia
1997
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. New England Journal Of Medicine 1997, 337: 809-815. PMID: 9295240, DOI: 10.1056/nejm199709183371202.Peer-Reviewed Original ResearchConceptsClozapine groupExtrapyramidal side effectsHaloperidol groupRefractory schizophreniaSide effectsAntipsychotic drugsDouble-blind comparative studyVeterans Affairs Medical CenterMore outpatient servicesNegative Syndrome ScaleComparison of clozapineLower symptom levelsSimilar overall costsHospitalized patientsTreat analysisTardive dyskinesiaPsychiatric reasonsLower incidenceMedical CenterOutpatient servicesHospital usePatientsSyndrome ScaleClozapineHaloperidol